Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17317394 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL193365 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL7749147 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL385010 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL18604185 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL385721 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL51478 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL7065072 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL2331938 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE | |
| SCHEMBL383271 | 1.00 | CHRM2 (0.44) | CHRM2ADRA2AADORA3CHRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071080-B2 | May be imidazolium, pyrazolium, pyridinium, pyrimidinium or tetraalkylphosphonium salts; washing (cleaning) and/or conditioning keratin materials, and especially the hair. | L'OREAL (FR) | 2011-12-06 | — | — | US | claimed |
| EP-1362572-B2 | Use of at least one particular organic salt for cleansing and/or conditioning keratinous materials, use of a particular organic salt as conditioning agent for said materials and process for cosmetic treatment | OREAL (FR) | 2011-08-17 | — | — | EP | claimed |
| EP-1362572-B1 | Use of at least one particular organic salt for cleansing and/or conditioning keratinous materials, use of a particular organic salt as conditioning agent for said materials and process for cosmetic treatment | OREAL (FR) | 2008-04-16 | — | — | EP | claimed |
| US-20040005286-A1 | Organic salt conditioner, organic salt-containing composition, and uses thereof | L'OREAL (FR) | 2004-01-08 | — | — | US | claimed |
| US-12550617-B2 | Piezoelectric composite materials having improved piezoelectric properties | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-4094304-B1 | PIEZOELECTRIC COMPOSITE MATERIALS WITH IMPROVED PIEZOELECTRIC PROPERTIES | MICHELIN & CIE (FR) | 2025-04-16 | — | — | EP | disclosed |
| EP-3402486-B1 | CCX168 FOR USE IN THE TREATMENT OF C3 GLOMERULOPATHY | CHEMOCENTRYX INC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3474845-B1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11793771-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11779576-B2 | Method of treating C3 glomerulopathy | CHEMOCENTRYX, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230117425-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-2381778-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010075257-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060110350-A1 | Composition comprising electrophilic monomers and particular organic salts, and use thereof for cosmetic treatment of keratin materials | L'OREAL S.A. (FR) | 2006-05-25 | — | — | US | disclosed |
| US-20040005286-A1 | Organic salt conditioner, organic salt-containing composition, and uses thereof | L'OREAL (FR) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CHRM2 342/4885ADRA2A 190/4885ADORA3 121/4885 |
| US-20230117425-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, IL2RA, C3AR1 | CHRM2 32/4885ADRA2A 97/4885ADORA3 278/4885 |
| US-11779576-B2 | Method of treating C3 glomerulopathy | C3AR1, C5, C5AR1 | CHRM2 1032/4885ADRA2A 1058/4885ADORA3 632/4885 |
| US-20040005286-A1 | Organic salt conditioner, organic salt-containing composition, and uses thereof | KRT18, HCN4, PRKDC | CHRM2 3434/4885ADRA2A 4852/4885ADORA3 2626/4885 |
| US-11793771-B2 | Immunomodulator compounds | IL2, IL2RA, C3AR1 | CHRM2 32/4885ADRA2A 97/4885ADORA3 278/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CHRM2 342/4885ADRA2A 190/4885ADORA3 121/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CHRM2 342/4885ADRA2A 190/4885ADORA3 121/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | CHRM2 143/4885ADRA2A 171/4885ADORA3 77/4885 |
| US-12550617-B2 | Piezoelectric composite materials having improved piezoelectric properties | PIEZO1, PIP5K1C, PIP5K1A | CHRM2 1648/4885ADRA2A 1977/4885ADORA3 597/4885 |
| US-20060110350-A1 | Composition comprising electrophilic monomers and particular organic salts, and use thereof for cosmetic treatment of keratin materials | KRT18, PRKDC, CUTA | CHRM2 3142/4885ADRA2A 4746/4885ADORA3 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.